Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oxford BioMedica ( (GB:OXB) ) has issued an update.
Oxford Biomedica has announced its total voting rights as of 31 December 2024, amounting to 105,961,906 ordinary shares. This figure is significant for shareholders to calculate their interests under the FCA’s Disclosure Guidance and Transparency Rules, highlighting the company’s commitment to transparency and regulatory compliance.
More about Oxford BioMedica
Oxford Biomedica PLC (LSE: OXB) is a leading contract development and manufacturing organization (CDMO) in the cell and gene therapy sector. The company is renowned for its expertise in viral vector development and manufacturing, collaborating with innovative pharmaceutical and biotechnology firms globally. OXB’s capabilities range from early development to commercialization, supported by advanced technologies and regulatory expertise. Headquartered in Oxford, UK, it operates facilities in Oxfordshire, France, and the US.
Average Trading Volume: 1,648
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $557.1M
For detailed information about OXB stock, go to TipRanks’ Stock Analysis page.
